BackJasper Therapeutics- Warrants (24/09/2026) Overview
Jasper Therapeutics Inc - Warrants (24/09/2026)

Jasper Therapeutics- Warrants (24/09/2026) Return on Equity

Valuation check: JSPRW's ROE is -2165.39%, below the sector sector average of 11.64%.

Get informed when a big investor buys or sells

+ Follow

ROE

-2165.39%

Return on Equity

-2165.39%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Jasper Therapeutics- Warrants (24/09/2026) (JSPRW) FAQ

Jasper Therapeutics- Warrants (24/09/2026)'s return on equity stands at -2165.39%. That is below the sector sector average of 11.64%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Jasper Therapeutics- Warrants (24/09/2026) sits lower the its sector benchmark (11.64%) with a ROE of -2165.39%. That is roughly 18708.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -2165.39% for Jasper Therapeutics- Warrants (24/09/2026) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Jasper Therapeutics- Warrants (24/09/2026)'s ROE evolved across reporting periods, while the comparison chart places JSPRW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.